Orforglipron

Research Goal: Analyzing the efficacy of a small-molecule GLP-1RA for gastric emptying inhibition and satiety signaling via oral administration.

Route

Oral

Dose range

12 mg – 45 mg

Frequency

Once per day

Cycle length

Chronic administration for metabolic research

Not currently stocked by N1 Aminos. Browse what is in stock →

Overview

Research Goal: Analyzing the efficacy of a small-molecule GLP-1RA for gastric emptying inhibition and satiety signaling via oral administration.

Preparation: Administered as an oral tablet. No reconstitution or injection required.

Studied benefits

  • A non-peptide, oral GLP-1 receptor agonist designed for weight management and type 2 diabetes
  • Unlike injectable GLP-1s, it offers high bioavailability in pill form, leading to significant weight loss and improved glycemic control by suppressing appetite and slowing gastric emptying

Reported side effects

  • Primarily gastrointestinal, including nausea, vomiting, and diarrhea, particularly during the initial dosing phase
  • These effects typically diminish over time with consistent use

Protocol

Dosing Schedule (Oral)

Educational reference only. Not medical advice. Research compounds are not approved for human use. Full disclaimer.

WeekDaily Dose (mg)FrequencyLog
Weeks 1–412 mgOnce Daily+ Log
Weeks 5–824 mgOnce Daily+ Log
Weeks 9+36–45 mgOnce Daily (Maintenance)+ Log

Frequency

Once per day.

Timing

Taken with or without food, consistently at the same time.

Cycle length

Chronic administration for metabolic research.

Context

Lifestyle considerations

Follow a high-protein, balanced diet to preserve lean muscle mass while this non-peptide GLP-1 receptor agonist works to manage appetite and blood glucose levels. Incorporate regular physical activity to maximize metabolic expenditure and improve cardiovascular health markers during the weight-management protocol. Ensure 7–9 hours of quality sleep to regulate hunger hormones like ghrelin, which works in synergy with the compound’s satiety-promoting mechanism. Maintain optimal hydration and monitor for gastrointestinal side effects, utilizing smaller, more frequent meals if nausea or delayed gastric emptying occurs.

Evidence

Research summaries

Efficacy and safety of oral orforglipron in patients with type 2 diabetes

Findings: Drops blood sugar big time, sheds pounds (up to 10kg), easier pill over shots for diabetes control.

Orforglipron, a mouth-friendly GLP-1 mimic (not real peptide but acts like one), fights type 2 diabetes hunger hormone. Phase 2 trial: diabetes patients took escalating doses vs. placebo or shot rival. At 36-45mg, HbA1c (sugar average) plunged vs. others; weight fell 10kg max (placebo just 2kg). Like appetite brake plus fat burner. Mild nausea common but faded. Game-changer: daily pill matches injections sans needles, for steady energy sans sugar crashes. Helps overweight teens dodge family diabetes too.

Read the study ↗

Orforglipron in type 2 diabetes mellitus and obesity

Findings: Weight loss up to 13kg, shrinks waist 8cm+, lowers blood pressure.

Review hit trials: orforglipron slashed HbA1c 2.1%, weight 10+kg, waist notably. Tops GLP-1s for slimming in meta-checks. Pressure eased sans diabetes even. Nausea/vomiting mild-higher doses, ramp slow. Oral ease beats shots for obesity fight, steady energy for active life. Like reset button on overeating cycle.

Read the study ↗

Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment

Findings: 72-week weight drop superior placebo, consistent GLP-1 safety.

Phase 3 obese adults: 6-36mg orforglipron + diet/activity beat placebo on % weight loss. Gut-similar sides. Pill freedom for long-haul slimming, sustained pep.

Read the study ↗

Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes

Findings: HbA1c down 1%+, manages early diabetes well.

Early diabetes trial: doses crushed placebo on sugar control. Oral win for new cases, prevents worsening.

Read the study ↗
More references (4)

Identification

Chemistry

cas
2212020-52-3 (free base)
formula
C₄₈H₄₈F₂N₁₀O₅
molecular weight
882.97 g/mol (882.38 g/mol reported variant)
source
Synthetic; rationally designed through structure-based medicinal chemistry
biosynthesis
Non-ribosomal; chemically synthesized through multi-step organic synthesis
type
Complex bicyclic/polycyclic small molecule; non-peptide structure fundamentally distinct from GLP-1 peptide sequence

Keep exploring

Related peptides

Educational use only. The protocols shown summarise published research and community practice for informational purposes. They are not medical advice, not a prescription, and not a recommendation to use any compound. Research peptides are generally not approved for human use. Consult a licensed clinician. Full disclaimer.
Ask the advisor